Business Overview / Sources of Revenue

Corcept Therapeutics (NASDAQ: CORT) is a biopharmaceutical company focused on discovering and developing medications that modulate cortisol to treat endocrine, oncologic, metabolic, and neurologic disorders.[1] The company generates revenue primarily through the commercialization of pharmaceutical products, with total revenue of $741.17 million over the past 12 months.[2]

The company's main revenue source is its flagship product **Korlym**, approved for treating Cushing's syndrome, a rare condition characterized by excessive cortisol production.[1] Korlym is sold directly to patients in the United States through specialty pharmacies and distributors.[1] Beyond Korlym, Corcept has developed a portfolio of over 1,000 proprietary cortisol modulators, with lead compound relacorilant currently in Phase 3 trials for Cushing's syndrome and advanced ovarian cancer.[1] The search results do not provide a specific percentage breakdown of revenue sources between individual products.

Revenue Growth Potential and Recurrence

Corcept Therapeutics demonstrates a **high share of recurring revenue** through its pharmaceutical business model, primarily driven by Korlym (mifepristone) for Cushing's syndrome. Pharmaceutical products generate predictable, repeat customer purchases, creating a stable revenue base. The company generated $716.08 million in revenue over the last 12 months with strong profitability metrics, including an 18.66% profit margin.[1]

**Growth Potential:** Revenue growth faces mixed prospects. Q3 2025 showed net product revenue of $207.6 million, up 13.8% year-over-year, driven by 42.5% volume increases offset by 20.2% average price declines due to authorized-generic competition.[2] Near-term catalysts include two pivotal PDUFAs (regulatory approvals) for pipeline candidates, particularly relacorilant for hypercortisolism.[2] However, the company remains small at $675 million in annual revenue, operating in a competitive market where scale matters.[3] Specific 5+ year growth rate projections are unavailable from the search results, but growth will depend on regulatory approvals, authorized-generic dynamics, and pipeline execution rather than organic market expansion.

Economic Moat Factors

Corcept Therapeutics possesses a **modest but developing economic moat** centered on unique assets and regulatory barriers rather than traditional moat characteristics.

**Unique Assets & Regulatory Barriers**: The company's proprietary compounds for treating hypercortisolism and other rare disorders represent valuable intellectual property. Korlym's market position and the upcoming relacorilant pipeline candidate create regulatory advantages through patent protection and FDA approval barriers that competitors must overcome.

**Limited Traditional Moats**: Corcept lacks strong switching costs, network effects, or significant economies of scale. The company faces pharmaceutical industry competition and patent expiration risks, with generic competition pressuring Korlym despite record prescriptions.

**Operational Constraints**: Recent capacity bottlenecks with specialty pharmacy vendors highlight the fragility of the current moat. Heavy reliance on Korlym creates vulnerability rather than moat strength.

**Assessment**: Corcept's moat is primarily **narrow and execution-dependent**, contingent on successfully scaling operations and advancing pipeline candidates like relacorilant to maintain competitive advantages.[1][3]

Leadership

**Joseph Belanoff, M.D.** serves as Chief Executive Officer, President, and Director of Corcept Therapeutics[3]. He is a **co-founder** of the company and has held the CEO position **since 1999**[3], making him a long-tenured leader with over 25 years in the role. In 2014, he was also appointed President[3]. Belanoff is a clinical faculty member at Stanford University's Department of Psychiatry and Behavioral Sciences since 1992[3]. The broader leadership team includes **Sean Maduck** (President, Endocrinology), **Roberto Vieira** (President, Oncology), **Atabak Mokari** (Chief Financial Officer), and **Amy Flood** (Chief Human Resources and Communications Officer)[2][6]. The search results do not specify Belanoff's ownership stake.

Financial Health

Based on the available search results, I can confirm that Corcept Therapeutics maintains strong financial health with a "GREAT" overall financial health score and particularly strong profitability and cash flow metrics[3]. The company reported a net margin of 18.51% and a return on equity of 20.10%[1].

However, the search results do not contain specific information about the company's cash-to-debt ratio, free cash flow, free cash flow margin, or share repurchase/dilution activity. To fully answer your question about balance sheet strength and capital allocation strategy, you would need to review the company's latest 10-K or 10-Q filings with the SEC.

Last updated Dec 3, 2025